Clinical Trial Update: Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating tirzepatide for weight loss as an intervention in early-stage hormone receptor-positive, HER2-negative breast cancer a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MOUNJARO (tirzepatide)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | Phase 2 | Status: RECRUITING